PRINCETON, NJ--(Marketwire - September 28, 2007) - Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company that develops and markets dermatology products, today announced that it has completed patient enrollment for its pivotal Phase 3 clinical study of Hyphanox™, a novel patented oral formulation of the antifungal agent itraconazole, for the treatment of toenail onychomycosis (nail fungus).
